GlassScriptPhysician profile
Marisol L Ocampo
NPI 1457859720
$32,342.36
in general payments reported to CMS, 2019-2025
84 companies · $7,582 in 2025
The $7,582 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,541 · 2022: $5,577 · 2023: $4,960 · 2024: $6,682 · 2025: $7,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $540 · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,192.90 |
| Consulting Fee | $540.00 |
| Education | $491.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,383.10 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $1,878.92 | 2021-2025 | Imfinzi, Enhertu, Datroway |
| Pfizer INC. | $1,866.31 | 2021-2025 | |
| Celgene Corporation | $1,594.94 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Genzyme Corporation | $1,547.96 | 2021-2025 | |
| Daiichi Sankyo INC. | $1,264.67 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,162.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $979.16 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $910.25 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $839.09 | 2021-2025 | |
| Beigene USA, INC. | $766.89 | 2021-2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $765.71 | 2021-2025 | Opdivo |
| Astellas Pharma US INC | $696.39 | 2021-2025 | Xtandi, Xospata, Padcev |
| Karyopharm Therapeutics INC. | $660.00 | 2021 | |
| Genentech USA, INC. | $658.61 | 2021-2025 | Tecentriq Hybreza, Polivy, Venclexta |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $637.21 | 2021-2023 | Kyprolis, Blincyto, Lumakras |
| Regeneron Healthcare Solutions, INC. | $598.45 | 2021-2025 | Libtayo |
| Array Biopharma INC | $553.94 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Scientific Affairs, LLC | $540.00 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $538.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $527.74 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $510.24 | 2021-2025 | |
| Seagen INC. | $486.28 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Epizyme, INC. | $460.59 | 2021-2023 | Tazverik |
| Springworks Therapeutics, INC. | $426.81 | 2024-2025 | Ogsiveo, Gomekli |
| Tempus Ai, INC | $390.59 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $389.44 | 2022-2025 | Clonoseq |
| Sirtex Medical INC | $356.07 | 2021-2022 | |
| Exelixis INC. | $352.17 | 2021-2025 | Cabometyx |
| Emd Serono, INC. | $335.59 | 2021-2025 | Bavencio |
| Sumitomo Pharma America, INC. | $320.97 | 2023-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $295.58 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $288.15 | 2021-2023 | Epkinly, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $278.44 | 2024-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Beone Medicines USA, INC. | $278.15 | 2025 | Tevimbra, Brukinsa |
| Deciphera Pharmaceuticals INC. | $271.03 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Myovant Sciences INC. | $232.39 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $231.83 | 2022-2025 | |
| Sobi, INC | $230.44 | 2023-2025 | |
| Mirati Therapeutics, INC. | $219.44 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $213.55 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $207.73 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Kite Pharma, INC. | $171.87 | 2021-2023 | Yescarta |
| Lilly USA, LLC | $169.90 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $167.74 | 2021-2025 | Onivyde, Somatuline Depot |
| Myriad Genetic Laboratories, INC. | $163.69 | 2021-2025 | Myrisk |
| Morphosys, US INC. | $157.05 | 2021-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $152.48 | 2023-2025 | Fotivda |
| Genmab U.S., INC. | $132.41 | 2023-2024 | Epkinly |
| Alexion Pharmaceuticals, INC. | $121.04 | 2021-2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $109.36 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $106.13 | 2021-2024 | Xarelto |
| Immunogen, INC. | $105.98 | 2023 | Elahere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.53 | 2024-2025 | Gilotrif |
| Blueprint Medicines Corporation | $95.54 | 2024-2025 | Ayvakit |
| Stemline Therapeutics INC. | $94.28 | 2024-2025 | Orserdu |
| Tersera Therapeutics LLC | $90.20 | 2025 | Zoladex |
| Foundation Medicine, INC. | $87.09 | 2021-2023 | |
| Sanofi US Services INC. | $83.20 | 2025 | |
| Dendreon Pharmaceuticals LLC | $72.93 | 2024-2025 | Provenge |
| Acceleron Pharma, INC. | $71.77 | 2021 | |
| Kyowa Kirin, INC. | $71.75 | 2021-2022 | |
| Tolmar, INC. | $68.64 | 2023-2025 | Rubraca, Eligard |
| Gilead Sciences, INC. | $65.88 | 2022-2025 | Trodelvy |
| Geron Corporation | $59.83 | 2025 | Rytelo |
| Legend Biotech USA INC. | $59.43 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $59.28 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $57.02 | 2024-2025 | Pyrukynd |
| Pharmaand Gmbh | $54.14 | 2025 | Rubraca |
| Pharmacosmos Therapeutics INC. | $52.85 | 2024 | Cosela |
| Syndax Pharmaceuticals, INC. | $47.13 | 2025 | |
| G1 Therapeutics, INC. | $40.60 | 2022-2023 | Cosela |
| Caris Mpi, INC. | $38.04 | 2025 | Mi Cancer Seek |
| Apellis Pharmaceuticals, INC. | $35.35 | 2023-2024 | Empaveli |
| Recordati_rare_diseases_inc. | $35.12 | 2024 | Sylvant |
| Sun Pharmaceutical Industries INC. | $30.68 | 2025 | |
| Clovis Oncology, INC. | $27.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $22.29 | 2021 | |
| Cti Biopharma Corp. | $21.30 | 2023 | Vonjo |
| Invivyd INC | $21.05 | 2025 | Pemgarda |
| Blue Earth Diagnostics | $19.50 | 2022 | |
| Dova Pharmaceuticals | $19.43 | 2021 | |
| Nuvation Bio INC. | $19.04 | 2025 | Ibtrozi |
| Tolmar Pharmaceuticals, INC. | $16.66 | 2022 |
Drugs and devices associated with these payments
Erleada $1,437Reblozyl $908Enhertu $761Keytruda $640Orgovyx $598Sarclisa $580Carvykti $553Lenvima $538Brukinsa $523Xtandi $508Braftovi $493Rybrevant $476Opdivo $470Kisqali $465Xt Cdx $391Darzalex $365Mektovi $365Lynparza $354Libtayo $351Tukysa $299Ojjaara $292Elahere $284Ogsiveo $281Talzenna $277Tevimbra $269Tecvayli $255Monjuvi $242Imfinzi $235Pluvicto $225Venclexta $224Jakafi $223Krazati $219Inqovi $214Lonsurf $214Rezlidhia $208Tavalisse $208Datroway $196Vonjo $195Lorbrena $181Ayvakit $179Epkinly $171Padcev $168Fabhalta $167Stivarga $161Clonoseq $160Pomalyst $156Fotivda $152Talvey $140Welireg $138Zepzelca $138Adcetris $136Pemazyre $133Lutathera $130Qinlock $129Bosulif $127Verzenio $123Akeega $121Elrexfio $120Yescarta $119Ibrance $118Tivdak $117Nubeqa $116Calquence $115Onivyde $114Ninlaro $108Rubraca $106Jaypirca $105Breyanzi $104Kyprolis $104Retevmo $103Piqray $102Gavreto $100Xalkori $99.80Orserdu $94.28Imbruvica $93.33Myrisk $91.87Zoladex $90.20Ultomiris $87.39Cabometyx $85.69Tibsovo $84.73Xofigo $81.64Tecentriq Hybreza $81.50Jemperli $79.74Blincyto $78.79Zejula $76.10Zynyz $75.46Cosela $73.26Fruzaqla $72.97Provenge $72.93Inlyta $66.51Alunbrig $63.54Polivy $63.15Rytelo $59.83Doptelet $57.03Pyrukynd $57.02Tecentriq $56.70Gilotrif $50.86Tabrecta $50.38Tazverik $45.16Bavencio $44.59
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Ocampo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.